Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Cancer Vaccines Targeting HER2/neu for Early Breast Cancer

Authors
Ryu, Woo SangSon, Gil Soo
Issue Date
Mar-2010
Publisher
KOREAN BREAST CANCER SOC
Keywords
Breast neoplasms; Dendritic cells; HER2/neu; Vaccines
Citation
JOURNAL OF BREAST CANCER, v.13, no.1, pp.5 - 13
Indexed
SCIE
SCOPUS
KCI
OTHER
Journal Title
JOURNAL OF BREAST CANCER
Volume
13
Number
1
Start Page
5
End Page
13
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/116959
DOI
10.4048/jbc.2010.13.1.5
ISSN
1738-6756
Abstract
Recent studies of immune responses to pathogens have identified pathogen-associated molecular patterns recognized by the innate immune system through specialized receptors called toll-like receptors (TLRs). Signaling through these receptors initiates robust immune responses. By exploiting TLR signaling pathways, immunity to tumor-associated antigens may be generated Many tumor-associated antigens are involved in the regulation of tumor phenotype or carcinogenesis. Immune targeting of these antigens may either alter the tumor phenotype, yielding a more treatable tumor, or eradicate early tumor stem cells preventing tumor formation. The oncoprotein HER2/neu, which is often overexpressed in ductal carcinoma in situ (DCIS), may provide such a target. Immune responses directed against HER2/neu may eliminate the disease, make tumors more amenable to anti-estrogen therapy, or prevent escape of hormone-resistant tumor phenotypes. Effective breast cancer prevention in preclinical studies utilizing murine HER2/neu transgenic models has stimulated interest in, and optimism regarding, protective breast cancer vaccines in humans. Induction of anti-HER2/neu T cell (CD4+ and CD8+) and B cell responses has been demonstrated in an ongoing clinical study targeting HER2/neu using a TLR agonist-primed dendritic cell vaccine Moreover, these vaccinations lead to reductions in both HER2/neu expression and extent of DCIS HER2/neu expression and aromatase activity have recently been linked through the intermediary cyclooxygenase 2 (COX-2) This convergence between growth factor and hormone mediated pathways provides additional support for the notion that a significant number of breast cancers may be prevented through effective immune targeting of HER2/neu. As progress is made towards the development of vaccines for breast cancer prevention, the contributions of immune-mediated effecter and inhibitory mechanisms to the pathogenesis of HER2/neu overexpressing breast cancer will need to be better understood.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Son, Gil Soo photo

Son, Gil Soo
College of Medicine (Department of Medical Science)
Read more

Altmetrics

Total Views & Downloads

BROWSE